Table 3:
Open in new tab

mean PAS for responders and non-responders to immune checkpoint inhibition

Primary tumor tissue (n = 31)Metastatic tumor tissue (n = 34)
Pathway (mean [range])Responder (n = 14)Non-responder (n = 17)P-valueResponder (n = 15)Non-responder (n = 19)P-value
TGF-β50.86 [36–60]50.00 [32–63]0.75153.87 [42–68]56.84 [45–77]0.265
Hh33.64 [24–49]32.06 [19–48]0.56935.73 [27–45]41.63 [31–58]0.038
MAPK55.71 [25–66]56.53 [43–73]0.81047.47 [35–69]46.21 [34–59]0.664
AR28.43 [20–37]27.41 [20–35]0.54228.47 [21–37]27.84 [20–39]0.721
NOTCH67.50 [52–85]64.53 [53–74]0.30163.27 [50–76]62.79 [43–84]0.880
PI3K37.71 [25–49]38.59 [30–56]0.74139.60 [30–50]40.26 [31–54]0.784
JAK/STAT1-254.23 [20–77]56.25 [28–84]0.78445.53 [14–80]41.17 [16–79]0.562
NFκB65.92 [35–82]69.45 [51–80]0.47658.15 [35–79]61.94 [40–79]0.441
Primary tumor tissue (n = 31)Metastatic tumor tissue (n = 34)
Pathway (mean [range])Responder (n = 14)Non-responder (n = 17)P-valueResponder (n = 15)Non-responder (n = 19)P-value
TGF-β50.86 [36–60]50.00 [32–63]0.75153.87 [42–68]56.84 [45–77]0.265
Hh33.64 [24–49]32.06 [19–48]0.56935.73 [27–45]41.63 [31–58]0.038
MAPK55.71 [25–66]56.53 [43–73]0.81047.47 [35–69]46.21 [34–59]0.664
AR28.43 [20–37]27.41 [20–35]0.54228.47 [21–37]27.84 [20–39]0.721
NOTCH67.50 [52–85]64.53 [53–74]0.30163.27 [50–76]62.79 [43–84]0.880
PI3K37.71 [25–49]38.59 [30–56]0.74139.60 [30–50]40.26 [31–54]0.784
JAK/STAT1-254.23 [20–77]56.25 [28–84]0.78445.53 [14–80]41.17 [16–79]0.562
NFκB65.92 [35–82]69.45 [51–80]0.47658.15 [35–79]61.94 [40–79]0.441
Table 3:
Open in new tab

mean PAS for responders and non-responders to immune checkpoint inhibition

Primary tumor tissue (n = 31)Metastatic tumor tissue (n = 34)
Pathway (mean [range])Responder (n = 14)Non-responder (n = 17)P-valueResponder (n = 15)Non-responder (n = 19)P-value
TGF-β50.86 [36–60]50.00 [32–63]0.75153.87 [42–68]56.84 [45–77]0.265
Hh33.64 [24–49]32.06 [19–48]0.56935.73 [27–45]41.63 [31–58]0.038
MAPK55.71 [25–66]56.53 [43–73]0.81047.47 [35–69]46.21 [34–59]0.664
AR28.43 [20–37]27.41 [20–35]0.54228.47 [21–37]27.84 [20–39]0.721
NOTCH67.50 [52–85]64.53 [53–74]0.30163.27 [50–76]62.79 [43–84]0.880
PI3K37.71 [25–49]38.59 [30–56]0.74139.60 [30–50]40.26 [31–54]0.784
JAK/STAT1-254.23 [20–77]56.25 [28–84]0.78445.53 [14–80]41.17 [16–79]0.562
NFκB65.92 [35–82]69.45 [51–80]0.47658.15 [35–79]61.94 [40–79]0.441
Primary tumor tissue (n = 31)Metastatic tumor tissue (n = 34)
Pathway (mean [range])Responder (n = 14)Non-responder (n = 17)P-valueResponder (n = 15)Non-responder (n = 19)P-value
TGF-β50.86 [36–60]50.00 [32–63]0.75153.87 [42–68]56.84 [45–77]0.265
Hh33.64 [24–49]32.06 [19–48]0.56935.73 [27–45]41.63 [31–58]0.038
MAPK55.71 [25–66]56.53 [43–73]0.81047.47 [35–69]46.21 [34–59]0.664
AR28.43 [20–37]27.41 [20–35]0.54228.47 [21–37]27.84 [20–39]0.721
NOTCH67.50 [52–85]64.53 [53–74]0.30163.27 [50–76]62.79 [43–84]0.880
PI3K37.71 [25–49]38.59 [30–56]0.74139.60 [30–50]40.26 [31–54]0.784
JAK/STAT1-254.23 [20–77]56.25 [28–84]0.78445.53 [14–80]41.17 [16–79]0.562
NFκB65.92 [35–82]69.45 [51–80]0.47658.15 [35–79]61.94 [40–79]0.441
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close